Medexus Pharmaceuticals Inc (MDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medexus Pharmaceuticals Inc (MDP) has a cash flow conversion efficiency ratio of 0.150x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$7.83 Million) by net assets (CA$52.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medexus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Medexus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medexus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medexus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Standard Life PLC
LSE:SDLF
|
0.042x |
|
SunCar Technology Group Inc.
NASDAQ:SDA
|
0.000x |
|
Intertek Group PLC
LSE:ITRK
|
0.124x |
|
Aquila European Renewables Income PLC
LSE:AERI
|
N/A |
|
Fonar Corporation
NASDAQ:FONR
|
0.001x |
|
Osteonic Co. Ltd
KQ:226400
|
0.017x |
|
Shinyoung Waco
KO:005800
|
0.040x |
|
CammSys Corp
KQ:050110
|
0.139x |
Annual Cash Flow Conversion Efficiency for Medexus Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Medexus Pharmaceuticals Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$52.14 Million | CA$24.03 Million | 0.461x | -25.31% |
| 2024-03-31 | CA$30.32 Million | CA$18.71 Million | 0.617x | +1027.10% |
| 2023-03-31 | CA$-26.37 Million | CA$-1.44 Million | 0.055x | -41.57% |
| 2022-03-31 | CA$-12.59 Million | CA$-1.18 Million | 0.094x | -66.48% |
| 2021-03-31 | CA$18.02 Million | CA$5.04 Million | 0.280x | +492.21% |
| 2020-03-31 | CA$24.28 Million | CA$-1.73 Million | -0.071x | +64.47% |
| 2019-03-31 | CA$9.67 Million | CA$-1.94 Million | -0.201x | +93.63% |
| 2018-03-31 | CA$948.80K | CA$-2.99 Million | -3.152x | -312.90% |
| 2017-03-31 | CA$-637.35K | CA$-943.53K | 1.480x | +256.80% |
| 2016-03-31 | CA$1.05 Million | CA$-990.96K | -0.944x | +32.67% |
| 2015-03-31 | CA$2.57 Million | CA$-3.61 Million | -1.402x | -122.88% |
| 2014-03-31 | CA$7.22 Million | CA$-4.54 Million | -0.629x | -11814.05% |
| 2013-03-31 | CA$1.70 Million | CA$-8.96K | -0.005x | -1420.74% |
| 2012-03-31 | CA$391.64K | CA$-136.00 | 0.000x | -- |
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more